Investor relations

Thank you for your interest in NEXGEL! Whether you are an existing shareholder or interested in joining our journey, we invite you to be a part of our mission to bring superior products to the customers that we serve every day. From thermoregulation and pain relief, to beauty treatments, NEXGEL’s unique hydrogels are some of the gentlest on the market.

We have continuously served leading companies in the healthcare and medical device markets for 23 years. One of only three electron-beam hydrogel facilities in the United States, NEXGEL’s Langhorne facility is one of the most trusted in the space. Using NEXGEL’s unique technology, large and small companies alike can confidently build their products and deliver great value.

We have a strong track record of innovation and continuous service to the healthcare markets. It’s only getting better from here as we broaden our services and expand into new markets and consumer segments.

Company news

Check out what we've been up to

Board of Directors

Mr. Nachum Stein

Mr. Stein has served as the Executive Chairman of our Board of Director since September 10, 2019. Mr. Stein is managing partner of HSI Partnership, an industrial and real estate investment family partnership. Mr. Stein previously served as Co-Chairman of the Board of Directors of Coleman Cable Co., a publicly traded company until its sale in 2014 for more than $700 million. In 1987, he founded American European Group, a private insurance holding company (“AEG”). Mr. Stein is Chairman and Chief Executive Officer of AEG. Mr. Stein and his family currently own a majority of AEG. Mr. Stein is a former Chairman of the Board of Directors of Beth Jacob of Boro Park, the largest Jewish Community School for girls in the United States, and also a former member of the Board of Directors of Machon Bais Yakov Hilda Birn High School, and a member of the Board of Trustees of Agudath Israel of America as well as active in various community philanthropies, and committees of Jewish institutions of higher studies.

Mr. David Stefansky

Mr. Stefansky has served as the Executive Chairman of our Board of Director since September 10, 2019.
Mr. Stefansky is a principal at Bezalel Partners, a private company engaged in principal investments and advisory services for early stage companies. He previously served in senior roles at investment banks and in executive and corporate director roles for private and publicly traded emerging growth companies in various sectors.

Dr. Jerome Zeldis

Dr. Jerome B. Zeldis was Chief Medical Officer and President of Clinical Research, Regulatory, and Safety at Sorrento Therapeutics. He was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and had been at Celgene since February, 1997 before joining Sorrento. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry). Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. . He has been a board member of several start-up biotechnology companies and is currently on the board of the PTC Corporation (PTCT), Soligenix, Trek Therapeutics and Bionor Pharma. He has published 122 peer reviewed articles and created 43 US patents.

Sec filings

Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.